Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Brandon Weiss, Leor Roseman, Bruna Giribaldi, David J. Nutt, Robin L. Carhart-Harris, David Erritzøe
International Journal of Mental Health and Addiction March 7, 2024 DOI: 10.1007/s11469-024-01253-9 via OpenAlex
Summary
AI-generated from the abstractAcute psychological experiences, particularly mystical experience and ego dissolution, partially account for how psilocybin therapy improves depression compared to escitalopram. In a phase 2 trial of patients with moderate-to-severe major depressive disorder, mystical experience and ego dissolution uniquely mediated the effect of treatment on depressive response. Higher levels of mystical experience, emotional breakthrough, and intense music-listening responses were also linked to greater antidepressant improvement. These findings suggest that acute psychological experiences play a causal mechanistic role in psilocybin therapy for depression.
Study at a glance
| Characteristics | Phase 2, double-blind, randomized, active comparator controlled trial Peer reviewed |
|---|---|
| Population | Patients with moderate-to-severe major depressive disorder |
| Interventions | Psilocybin Therapy Escitalopram Treatment |
| Duration | 6-week trial period |
| Topics | Depression Ego dissolution Mystical experience |
| Keywords | Psilocybin therapy psilocybin Depressive symptoms Antidepressant responses Successful treatment |
| Citations | 26 |
| Key finding | Mystical experience and ego dissolution uniquely mediated the effect of psilocybin therapy versus escitalopram on depressive response, and higher levels of these experiences were associated with greater antidepressant response. |
Abstract
Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.